Table 1.
Patient, tumor and treatment characteristics of patients in the pre- and post-anthracycline eras
| Pre-AE | Post-AE | P-value | |
|---|---|---|---|
| Age (%) | <0.001 | ||
| <56 years | 2,618 (46.3) | 3,553 (50.8) | |
| ≥56 years | 3,037 (53.7) | 3,445 (49.2) | |
| ALN metastasis (%) | <0.07 | ||
| <14 | 2,707 (47.9) | 3,467 (49.5) | |
| ≥14 | 2,948 (52.1) | 3,531 (50.5) | |
| Sex (%) | 0.94 | ||
| Male | 51 (0.9) | 64 (0.9) | |
| Female | 5,604 (99.1) | 6,934 (99.1) | |
| Tumor size (%) | <0.001 | ||
| ≤32 mm | 2,808 (53.3) | 3,195 (48.8) | |
| >32 mm | 2,459 (46.7) | 3,353 (51.2) | |
| Histology (%) | <0.001 | ||
| IDC | 4,476 (79.2) | 5,047 (72.1) | |
| ILC | 756 (13.4) | 1,077 (15.4) | |
| MDLC | 423 (7.4) | 874 (12.5) | |
| ER status (%) | <0.001 | ||
| Positive | 2,767 (48.9) | 3,618 (51.7) | |
| Negative | 1,155 (20.4) | 1,503 (21.5) | |
| Equivocal | 71 (1.3) | 12 (0.2) | |
| Unknown | 1,662 (29.4) | 1,865 (26.6) | |
| PR status (%) | <0.001 | ||
| Positive | 2,907 (41.5) | 2,310 (40.9) | |
| Negative | 2,099 (30) | 1,543 (27.3) | |
| Equivocal | 34 (0.5) | 64 (1.1) | |
| Unknown | 1,958 (28) | 1,738 (30.7) | |
| Radiation (%) | <0.001 | ||
| No radiation | 3,263 (57.7) | 2,959 (42.3) | |
| Radiation | 2,392 (42.3) | 4,039 (57.7) |